Algert Global LLC Takes Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Algert Global LLC acquired a new stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 113,435 shares of the company’s stock, valued at approximately $1,315,000. Algert Global LLC owned about 0.13% of Pediatrix Medical Group at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the second quarter worth about $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the second quarter worth about $33,000. Quest Partners LLC lifted its position in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after buying an additional 1,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Pediatrix Medical Group in the second quarter worth about $72,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MD shares. Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Mizuho boosted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. UBS Group boosted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $16.10.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Pediatrix Medical Group Trading Up 0.1 %

Shares of MD opened at $14.77 on Friday. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -4.83, a P/E/G ratio of 2.10 and a beta of 1.55. The stock’s 50-day moving average price is $13.17 and its 200 day moving average price is $10.18.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period in the previous year, the company posted $0.29 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. As a group, research analysts predict that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.